Fiche publication
Date publication
octobre 2025
Journal
Blood cancer journal
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis
,
Pr FEUGIER Pierre
,
Dr SONNTAG Cécile
Tous les auteurs :
Moreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A
Lien Pubmed
Résumé
Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when possible. Lenalidomide maintenance until progression is also recommended per international guidelines. This strategy has been developed over recent decades, based on results of phase 3 trials designed and conducted by different academic groups. With these therapeutic advances, the median overall survival (OS) for patients with MM has increased from 5 years in the 1990s, to over 15 years at present. Here, we present the contribution of the French myeloma cooperative group Intergroupe Francophone du Myélome (IFM) to these advances in the newly diagnosed transplant-eligible (NDTE) setting.
Mots clés
Humans, Multiple Myeloma, therapy, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, methods, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Melphalan, administration & dosage, Clinical Trials as Topic
Référence
Blood Cancer J. 2025 10 24;15(1):177
